FDA Approves Veklury for Treatment of COVID-19 in Pediatric Patients

News
Article

FDA has approved Veklury to treat COVID-19 in pediatric patients under 12 years of age.

Gilead Sciences announced on April 25, 2022 that FDA has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) for the treatment of pediatric patients who are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to sever COVID-19, including hospitalization or death. Patients must also be older than 28 days and weigh at least 3 kg.

This approval follows the recent sNDA approval for Veklury for adults and adolescent patients who are at high risk of progression to severe COVID-19. For pediatric patients who are at high risk for COVID-19 disease progression, a three-day Veklury treatment regimen is recommended to help prevent hospitalization. For currently hospitalized pediatric patients who do not require invasive mechanical ventilation and/or ECMO, a five-day treatment course is recommended.

“This approval means that remdesivir can potentially provide meaningful clinical improvement, by reducing disease progression and helping children recover from COVID-19 more quickly,” said Amina Ahmed, MD, Atrium Health-Levine Children’s Hospital in Charlotte, NC, in a press release. “We need proven antiviral treatment options, like remdesivir, that can help treat some of the most vulnerable in our society: children.”

“The expanded indication for Veklury for the treatment of children is a testament to the safety, tolerability and efficacy profile of this therapy, which has remained the foundational antiviral for COVID-19 treatment,” added Merdad Parsey, MD, PhD, chief medical officer, Gilead Sciences. “Effective and tolerable options for children require our best science and a dedicated focus. With the recent opening of our Gilead Pediatric Center of Excellence in Dublin, which is responsible for coordinating pediatric clinical trials for treatments for HIV, hepatitis B and COVID-19, we will continue our research to help address unmet treatment needs for children.”

Source: Gilead Sciences

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes